Biotica and GSK are collaborating to optimise a series of erythromycin analogues for anti-inflammatory indications.
Erythromycin is best known as an antibiotic but it and its semi-synthetic derivatives are used clinically to treat a range of inflammatory disorders. Biotica is working to create novel compounds with reduced anti-bacterial activity and enhanced anti-inflammatory activity, using the novoPT™ technology to create compounds which cannot be readily achieved using conventional medicinal chemistry.
Partnership with GSK
In January 2009, Biotica announced a research and license agreement with GlaxoSmithKline (GSK) on this programme. The work takes advantage of Biotica’s rich know-how and IP around bioengineered erythromycins, and GSK’s extensive experience of developing macrolides. During a three-year collaboration, Biotica and GSK are working together to create further new erythromycin analogues. GSK is responsible for product development and marketing.